Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
BeiGene, Ltd. (BGNE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/27/2023 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 02/25/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/06/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results|
Docs:
|
"BeiGene Reports First Quarter 2019 Financial Results CAMBRIDGE, Mass. and BEIJING, China, May 9, 2019 -- BeiGene, Ltd. , a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights, anticipated upcoming milestones and financial results for the first quarter of 2019. “We made good progress in each of our business areas, including strong commercial performance in the first quarter of 2019, as we prepare for our planned launches in China and first new drug application in the United States. Our team is continuing to expand across the globe, with new trials, new indications, and importantly, new hope for patients with cancer who may not have..." |
|
| 11/07/2018 |
8-K
| Quarterly results |
| 08/09/2018 |
8-K
| Quarterly results|
Docs:
|
"Investor Contact",
"BeiGene Reports Second Quarter 2018 Financial Results CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 -- BeiGene, Ltd. , a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights and financial results for the second quarter and first half of 2018. “We continued to make excellent progress with encouraging new clinical data, including initial topline data from pivotal trials for our lead drug candidates, zanubrutinib and tislelizumab,” said John V. Oyler, Founder, Chief Executive Officer and Chairman of BeiGene. “We have also continued to expand our clinical programs and have now enrolled more than 3,000 patients worldwide in over 50..." |
|
| 05/09/2018 |
8-K
| Quarterly results|
Docs:
|
"BeiGene Reports First Quarter 2018 Financial Results CAMBRIDGE, Mass. and BEIJING, China, May 09, 2018 -- BeiGene, Ltd. , a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights and financial results for the first quarter of 2018. “We continue to make great progress launching new clinical trials on a global scale for patients with a wide variety of cancers, where we believe our investigational treatments can have a profound impact,” said John V. Oyler, Founder, Chief Executive Officer, and Chairman of BeiGene. “We have now enrolled more than 2,300 patients worldwide in more than 30 clinical trials of our investigational agents as of..." |
|
| 11/13/2017 |
8-K
| Quarterly results |
| 08/09/2017 |
8-K
| Quarterly results|
Docs:
|
"BeiGene Reports Second Quarter 2017 Financial Results CAMBRIDGE, Mass. and BEIJING, China, August 9, 2017 — BeiGene, Ltd. , a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today reported business highlights and financial results for the second quarter and first six months of 2017. “This quarter has been transformative for BeiGene. Our announced strategic collaboration with Celgene, which is expected to close in the third quarter, is an important step in the buildout of our internal capabilities from a research organization into a fully integrated biopharmaceutical company with clinical development, manufacturing, and soon a commercial platform. The planned addition of Celgene's China commercial tea...",
"BeiGene Announces Proposed Public Offering CAMBRIDGE, Mass. and BEIJING, China, August 9, 2017 — BeiGene, Ltd. , a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced a public offering of its American Depositary Shares , each representing 13 of its ordinary shares, par value $0.0001 per share. BeiGene intends to offer and sell $125,000,000 of its ADSs, before underwriting discounts and commissions and estimated offering expenses. In addition, BeiGene expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of ADSs, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to wh...",
"BeiGene, Ltd. materials dated August 2017",
"BeiGene, Ltd. materials dated August 2017" |
|
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 11/10/2016 |
8-K
| Form 8-K - Current report |
| 08/10/2016 |
8-K
| Form 8-K - Current report |
| 05/11/2016 |
8-K
| Form 8-K - Current report |
|
|